Imago BioSciences (Imago BioSciences) Quality Rank

View and export this data going back to 2021. Start your Free Trial

What is Imago BioSciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Imago BioSciences Quality Rank Related Terms

Thank you for viewing the detailed overview of Imago BioSciences's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Imago BioSciences (Imago BioSciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imago BioSciences Inc (NAS:IMGO) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

329 Oyster Point Boulevard, 3rd Floor, South San Francisco, CA, USA, 94080

Website

https://www.imagobio.com

Imago BioSciences Inc is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF).

Executives

Laura G. Eichorn	officer: Chief Operating Officer	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Michael Arenberg	officer: See Remarks	10260 BUBB ROAD, CUPERTINO CA 95014
Hugh Jr Rienhoff	director, officer: Chief Executive Officer	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Amy E. Tapper	officer: See Remarks	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Jennifer Peppe	officer: See Remarks	IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FL, SOUTH SAN FRANCISCO CA 94080
Hsiangyi Chiang	officer: Senior Vice President Finance	C/O IMAGO BIOSCIENCES, INC., 329 OYSTER POINT BLVD. 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Blackstone Inc.	10 percent owner	345 PARK AVENUE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c.	10 percent owner	C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Clarus Ventures Iii Gp, L.p.	10 percent owner	C/O CLARUS VENTURES, 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Clarus Lifesciences Iii, L.p.	10 percent owner	101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
Stephen A Schwarzman	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Group Management L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings I/ii Gp L.l.c.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Holdings Ii L.p.	10 percent owner	C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
Laurie Keating	director	300 THIRD STREET, CAMBRIDGE MA 02142